Back

Ondine Biomedical trial shows 41% reduction in surgical site infections

Verifying
  • Ondine Biomedical’s LANTERN trial met its primary goal.
  • The study recorded a 41% reduction in infections within 30 days.
  • LANTERN enrolled 5,188 patients across 18 hospitals in the US and Canada.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Ondine Biomedical trial shows 41% reduction in surgical site infections - CoinPost Terminal